Company Release

23 June 2021 at 9:30 a.m. (Finnish time)

Nightingale Health Oyj (“Nightingale”) announced in February 2021 an early-access pilot of its at-home blood testing solution for 10,000 consumers in Finland.

As planned, the first phase of the pilot began in the second quarter of 2021 by providing consumers the opportunity to be the first users of Nightingale’s at-home testing solution. After opening registration, the at-home blood collection kit orders exceeded quickly the maximum number of participants for the first phase, and blood samples collected at home were shipped for analysis to Nightingale’s laboratory within June 2021.

Due to strong interest by consumers, Nightingale will launch the second phase of the at-home blood testing pilot in July 2021. The pilot will consist in total of three phases, and all phases are estimated to be completed by the end of 2021 in accordance with the original schedule.

Nightingale considers the successful launch of the at-home blood testing pilot as a major achievement, as enabling the blood collection at customers’ homes provides a logistically efficient solution to expand the availability of Nightingale’s technology rapidly to the global market.

For further information, please contact:

Teemu Suna, CEO

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks, we are creating a world-leading health data platform that enables preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.